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Clinical Case Letters 
Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With 
Intravenous Immunoglobulin and Tocilizumab 
 
 (This is a preprint version of an article submitted for publication in Indian Pediatrics. 
Changes may be made before final publication) 
 
Coronavirus disease (COVID-19) in children appears to be largely a benign condition. 
However, there are reports of children presenting significantly unwell across Europe and 
USA in the last couple of weeks with a new multisystem inflammatory syndrome [1]. We 
report a child with COVID-19 who had overlapping features of Toxic Shock Syndrome (TSS) 
and Kawasaki disease (KD). 
A previously well, eight-year-old boy presented with fever, cough and throat pain. He 
was admitted to a local hospital on day 4 of illness in view of high-grade fever spikes. 
Investigations showed neutrophilic leukocytosis (total white blood cell count 23,000/µL, 
Neutrophils 89%) with raised acute phase reactants (C-reactive protein, CRP 120 mg/L). 
Chest X-ray showed right upper and middle lobe infiltrates. Reverse transcriptase 
polymerase chain reaction (RT-PCR) for severe acute respiratory illness novel coronavirus 
2 (SARS-CoV2) was negative. Treatment was empirically started with ceftriaxone and 
azithromycin. Despite treatment for three days, he continued to have high fever, worsening 
respiratory symptoms and was referred to our hospital.  
On arrival, he was alert, had respiratory rate of 50/min, intercostal retractions and 




hypotension (80/31 mm Hg), warm extremities and a capillary refill time of 3 seconds. He 
was also noted to have a generalized non-pruritic erythematous skin rash, non-purulent 
bulbar conjunctivitis, cracked lips, strawberry tongue, edema of limbs, tender hepatomegaly 
and abdominal distention. Investigations in our hospital showed haemoglobin of 8.9 g/dL, 
neutrophil predominant leukocytosis (total count 17,600/µL, 86% neutrophils), platelet count 
3,95,000/µL, markedly raised  CRP (317 mg/L), raised erytherocyte sedimentation rates 
(115 mm/h), hyper-ferritinemia (Ferritin 1,496 ng/mL), hypoalbuminemia (2.6 g/dL), 
hyponatremia (133 mEq/L), normal kidney and liver function, and 2+ proteinuria. He was 
given a fluid bolus and treatment empirically started with piperacillin-tazobactam and 
doxycycline. When reassessed after 30 minutes, he was febrile, hypotensive and had 
increased work of breathing. He was shifted to the pediatric intensive care unit. The initial 
differential diagnoses were pneumonia with septic shock, COVID-19 penumonitis, KD and 
TSS.  High-flow nasal cannula (HFNC) support was started and antibiotics were modified to 
meropenem, vancomycin and clindamycin. The blood pressure was stable and urine output 
was normal. Intravenous Immunoglobulin (IVIG) was given (2 g/kg) with aspirin (75 mg once-
a-day). Echocardiogram did not show any abnormalities and repeat chest X-ray showed 
increased right-sided infiltrates. Repeat nasopharyngeal COVID-19 RT-PCR was positive. 
Multiplex PCR of nasopharyngeal aspirate (BioFire FilmArray) detected Coronavirus OC43 
and Human Rhino/Enterovirus. As he improved, he was gradually weaned off HFNC. Blood 
cultures showed no growth and antibiotics were changed to ceftriaxone. In light of the 
persistent high-grade fever and elevated CRP (121 mg/L), 72 hours after IVIG infusion, he 
was given tocilizumab (8 mg/kg IV over 2 hours). Twelve hours later, his fever spikes settled, 
and inflammatory parameters rapidly decreased to baseline (Fig. 1). He was noted to have 




The clinical characteristics of COVID-19 disease progression and outcome in children 
and young adults appear significantly milder compared to older individuals [2]. However, 
there is now a growing recognition of a small number of children presenting with a 
multisystem inflammatory syndrome. This rare syndrome shares common features with 
other pediatric inflammatory conditions, including Kawasaki disease, Staphylococcal and 
Streptococcal Toxic Shock, bacterial sepsis and macrophage activation syndrome. It can 
also present with unusual abdominal symptoms with elevated inflammatory markers. 
Recently 8 children have been reported to present with hyper-inflammatory shock [3].  This 
has been titled recently as Pediatric multisystem inflammatory syndrome temporally 
associated with COVID-19 and a case definition has been suggested [1]: a child presenting 
with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopenia) and 
evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, 
gastrointestinal or neurological disorder) with additional features, which may include fulfilling 
full or partial criteria for KD; exclusion of any other microbial cause, including bacterial 
sepsis, staphylococcal or streptococcal shock syndromes; and SARS-CoV-2 PCR 
testing may be positive or negative  
Our case fulfils these criteria. It is likely that cytokine storm (CS) is one of the major 
causes of acute respiratory distress syndrome (ARDS), multiorgan dysfunction and possibly 
pediatric multisystem inflammatory syndrome [4]. IL-6 is a key cytokine in this process and 
few studies suggest that CS is positively correlated with disease severity [5]. Various 
immunomodulators have been discussed and tried for controlling the inflammatory response 
[6]. Tocilizumab, an IL-6 receptor antagonist approved by the US FDA for treating of 
Cytokine Release Syndrome (CRS), is now in clinical trials for treating severe COVID-19 
pneumonia [7]. Tocilizumab blocks downstream signal transduction by binding membrane 




[8]. High CRP levels seen in our case shows that this inflammatory syndrome is likely 
mediated by IL-6. Our case suggests that immunomodulation with IVIG and IL-6 blockade 
can be an effective therapeutic strategy, which has a scientific rationale. It is clear from 
Europe and the USA that appearance of this syndrome in children follows the peak of 
infections in affected areas. The immunopathology behind this phenomenon is yet to 
ascertained. We believe that children across India may present with this inflammatory 
syndrome related to COVID-19 in the weeks ahead and would like to highlight this to 
pediatricians across India. Tocilizumab may prove to be an effective second line agent in 
IVIG refractory children with COVID-19 hyper-inflammatory syndrome 
Though most SARS-CoV2 infections in children are likely to present with mild 
features, some may develop a hyper-inflammatory syndrome, which may require treatment 
with IVIG and Tocilizumab. Pediatricians should be aware of such presentation and 
immunomodulatory treatment modalities. 
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Fig. 1 Trend of Inflammatory markers in the child with hyper-inflammatory syndrome and COVID-19. 
 
